CAS 202796-42-7

UCB 35625

CAS: 202796-42-7

UCB 35625 is a chemokine. Chemokines are small cytokines that play an important role in the chemotaxis of immune cells, including T-cells and monocytes. UCB 35625 binds to chemokine receptors and modulates their activity. UCB 35625 has been shown to be therapeutically useful for age-related macular degeneration (AMD) by reducing the accumulation of inflammatory cells in the retina. It also inhibits the recruitment of monocytes into atherosclerotic lesions, thereby reducing inflammation and inhibiting plaque formation. The binding of UCB 35625 to chemokine receptors may be due to allosteric modulation, which is a change in enzyme activity by binding to an effector molecule at a site other than the active site or substrate binding site.
UCB 35625 has been found to inhibit IL-8 production through interaction with CCR2 receptor type, as well as reduce neutrophil migration through interaction with CXCR1

Formula: C₃₀H₃₇Cl₂IN₂O₂

Purezza: Min. 95%

Peso molecolare: 655.4 g/mol

Ref: 3D-CIA79642

trans-J-113863

CAS: 202796-42-7

Trans-J-113863 serves as a potent antagonist of chemokine receptors CCR1 and CCR3, effectively inhibiting MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants, with respective half-maximal inhibitory concentrations (IC50) of 9.57 nM and 93.8 nM [1] [2].

Formula: C₃₀H₃₇Cl₂IN₂O₂

Colore e forma: Solid

Peso molecolare: 655.44

Ref: TM-T84888